Dimerix Ltd: ACTION3 Trial Recruitment and Multiregion Trial Site Update
Dimerix Ltd: First Paediatric Site Activated and Trial Update
Dimerix Ltd: First patient enters into Open Label Extension study
Dimerix Ltd: Appendix 4G and Corporate Governance Statement
Dimerix Ltd: Notification of Date of 2024 AGM
Dimerix Ltd: Change of Director's Interest Notice - HA & SP
Dimerix Ltd: Quarterly Appendix 4C and Activities Report
Dimerix Ltd: Adolescent Recruitment into ACTION3 Clinical Trial
Dimerix Ltd: Appendices 3Y and Late Lodgement Notice
Dimerix Ltd: Dimerix and Taiba enter into License Agreement for DMX-200
Dimerix Ltd: Dimerix Receives PIP Approval from the UK MHRA
Dimerix Ltd: Quarterly Appendix 4C and Activities Report
Dimerix Ltd: Change of Director's Interest Notice - SP
Dimerix Ltd: Change of Director's Interest Notice - NW & SP
Dimerix Ltd: Change of Director's Interest Notice - NW
Dimerix Ltd: Notification of upcoming expiry of Unlisted Options
Dimerix Ltd: Trading Halt
Dimerix Ltd: Dimerix Successfully Passes Efficacy Interim Analysis
Dimerix Ltd: Notification of upcoming expiry of Unlisted Options
Dimerix Ltd: PH3 Data Collection Complete for First Interim Analysis
No Data
No Data